PLZF overexpression in T-ALL cell line CEM-C7H2-2C8 downregulates glucocorticoid receptor (GR) and its target genes

Glucocorticoids (GCs) induce cell cycle arrest and apoptosis in lymphoid cells and constitute a central component in the treatment of lymphoid malignancies. The molecular basis of this clinically important phenomenon remains, however, poorly understood. Using whole genome expression profiling we have previously identified glucocorticoid response genes in children with acute lymphoblastic leukemia (ALL). The promyelocytic leukemia zinc finger (PLZF) appeared as one of the most promising candidate genes, which has been implicated in the pathogenesis of several leukemia types. We have already established that transgenic PLZF reduced the sensitivity to GC-induced apoptosis in the CEM-C7H2-2C8 leukemic cell line and knockdown of PLZF resulted in a small but significant increase in cell death in this cell line. The present study was proposed to find a plausible molecular explanation for this protective effect of PLZF against GC-induced cell death. It was found that doxycycline-regulated PLZF overexpression in the CCRF-CEM T-ALL cell line downregulates the GC-induced GR expression and its target genes, which resulted in reduced apoptosis induced by GC.

PLZF overexpression in T-ALL cell line CEM-C7H2-2C8 downregulates glucocorticoid receptor (GR) and its target genes

Glucocorticoids (GCs) induce cell cycle arrest and apoptosis in lymphoid cells and constitute a central component in the treatment of lymphoid malignancies. The molecular basis of this clinically important phenomenon remains, however, poorly understood. Using whole genome expression profiling we have previously identified glucocorticoid response genes in children with acute lymphoblastic leukemia (ALL). The promyelocytic leukemia zinc finger (PLZF) appeared as one of the most promising candidate genes, which has been implicated in the pathogenesis of several leukemia types. We have already established that transgenic PLZF reduced the sensitivity to GC-induced apoptosis in the CEM-C7H2-2C8 leukemic cell line and knockdown of PLZF resulted in a small but significant increase in cell death in this cell line. The present study was proposed to find a plausible molecular explanation for this protective effect of PLZF against GC-induced cell death. It was found that doxycycline-regulated PLZF overexpression in the CCRF-CEM T-ALL cell line downregulates the GC-induced GR expression and its target genes, which resulted in reduced apoptosis induced by GC.

___

  • Cidlowski JA, King KL, Evans-Storms RB, Montague JW, Bortner CD, Hughes FM Jr (1996). The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system. Recent Prog Horm Res 51: 457–490.
  • Geley S, Hartmann BL, Hattmannstorfer R, Loffler M, Ausserlechner MJ, Bernhard D, Sgonc R, Strasser-Wozak EM, Ebner M, Auer B et al. (1997). p53-induced apoptosis in the human T-ALL cell line CCRF-CEM. Oncogene 15: 2429–2437.
  • Laudet V, Gronemeyer H (2002). The Nuclear Receptor Facts Book. London, UK: Academic Press.
  • Martin PJ, Delmotte MH, Formstecher P, Lefebvre P (2003). PLZF is a negative regulator of retinoic acid receptor transcriptional activity. Nucl Recept 1: 6.
  • Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, Ball HJ, Lutterbach B, Hiebert SW, Licht J D (2000). The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Mol Cell Biol 20: 2075–2086.
  • Parson W, Kirchebner R, Muhlmann R, Renner K, Kofler A, Schmidt S, Kofler R (2005). Cancer cell line identification by short tandem repeat profiling: power and limitations. FASEB J 19: 434–436.
  • Ploner C, Rainer J, Niederegger H, Eduardoff M, Villunger A, Geley S, Kofler R (2008). The BCL2 rheostat in glucocorticoid- induced apoptosis of acute lymphoblastic leukemia. Leukemia 22: 370–377.
  • Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R (2004). Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11 (Suppl. 1): S45–S55.
  • Schmidt S, Rainer J, Riml S, Ploner C, Jesacher S, Achmuller C, Presul E, Skvortsov S, Crazzolara R, Fiegl M et al. (2006). Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood 107: 2061–2069.
  • Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henz G, Gadner H, Odenwald E, Riehm H (2000). Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin- Frankfurt-Münster. Leukemia 14: 2205–2222.
  • Tissing WJ, den Boer ML, Meijerink JP, Menezes RX, Swagemakers S, van der Spek PJ, Sallan SE, Armstrong SA, Pieters R (2007). Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 109: 3929–3935.
  • Wasim M, Carlet M, Mansha M, Greil R, Ploner C, Trockenbacher A, Rainer J, Kofler R (2010). PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis. J Steroid Biochem Mol Biol 120: 218–227.
  • Wasim M, Mansha M, Kofler A, Awan AR, Babar ME, Kofler R (2012). Promyelocytic leukemia zinc finger protein (PLZF) enhances glucocorticoid-induced apoptosis in leukemic cell line NALM6. Pak J Pharm Sci 25: 617–621.